ENDURA-2 — Depemokimab for COPD
Sponsored by GlaxoSmithKline (GSK)
"Does fear of COPD flare-ups keep you close to home?"
Concept
To determine if Depemokimab reduces the rate of moderate/severe exacerbations compared to placebo.
Key Eligibility Criteria
Below are the main inclusion and exclusion criteria for this study. The full eligibility assessment will be discussed with you by our research team during screening.
Key Inclusion Criteria
- Age 40–80 years
- Documented COPD for ≥12 months
- High Blood Eosinophil Count (BEC): ≥300 cells/µL at screening or ≥150 cells/µL with a history of ≥300 cells/µL
- Stable maintenance COPD therapy for ≥6 months
Key Exclusion Criteria
- Current diagnosis of asthma
- Other significant lung diseases
- Use of other respiratory biologics
Apply for this study
Fill out the form below to see if you qualify. Our research coordinators will contact you directly to discuss your eligibility — there's no obligation to participate.
Your information is kept confidential and only used for study eligibility purposes.
Advancing research, one participant at a time.
Clinical trials depend on volunteers like you. By participating, you gain access to potential new treatments while helping researchers discover safer, more effective therapies for everyone.
- Access to investigational treatments and expert medical care
- Close monitoring by our experienced research team
- Contribute to better treatments for future patients
- Confidential — your information is protected at every step